Hemostatic Agents Market by Product Type (Active, Passive, Combination), Specialty (Cardiology, Cath Lab, Trauma, General Surgery, Obgyn, Transplant, Oncology, Neurology, Orthopedic, Plastic Surgery, Dental), Size of Hospitals (Large Hospitals (500 + Beds), Medium Hospitals (250-499 Beds, Small Hospitals (Less than 250 Beds)) - Analysis & Forecast 2019-2030

Report ID : 56  |  Published Date : Apr 2020  |  Pages : 150  |  Region : Global  |  Report Code : MD-32

Hemostatic Agents Market Overview and Introduction

The global Hemostatic Agents market was estimated to be over US$ 3 Bn in 2018. It is anticipated to grow at a CAGR of 6.1% from 2019 to 2030. 

Hemostatic agents are used to control bleeding. A process that involves curbing the blood flow or bleeding through a blood vessel, or hemorrhage is called hemostasis. Hemostatic agents aid in hemostasis, by forming a clot at the injured area, thereby repairing the blood vessel. Primary hemostasis, secondary hemostasis, and fibrinolysis are some of the types of the hemostasis. Hemostatic agents are deployed to stem blood flow by promoting clotting, thereby enhancing the hemostasis through the coagulation process. These agents boost hemostasis by progressing primary hemostasis, increasing fibrin formation, or inhibiting fibrinolysis. Hemostatic agents play a pivotal role in curbing of bleeding or treating serious bleeds, thereby validating their usage in diverse therapeutic areas. They are not only used in hospital settings but also in military, clinics and home care settings.

Rise in research and development activities, adoption of hemostatic agents across various therapeutic areas is have crucial in contributing towards the growth of the global market. Additionally, steady rise in geriatric population that requires medical attention and surgery to treat various ailments, is fueling the demand for hemostatic agents, thus boosting the growth of the global market. The advent of advanced hemostatic agents is resulting in better patient outcomes and helping the surgeons to dispense fast-acting and safe treatments to their patients. However, adverse reactions could manifest themselves by the way of inflammation, hypotension or in some rare cases anaphylaxis and these allergic reactions are anticipated to impede the growth of this market.


Hemostatic Agents Market by Product 

On basis of product type the market is segmented into active, passive and combination. The active segment is expected to hold a dominant share owing to its ability to curb bleeding faster, it’s utilization to curtail serious bleeds and in high risk surgeries. Both the active and combination product types are anticipated to reflect a substantial CAGR compared to passive products in the forecast period.

Hemostatic Agents Market by specialty and Size of Hospitals

On the basis of specialty, the market is segmented into cardiology, cath lab, trauma, general surgery, obgyn, transplant, oncology, neurology, orthopedic, plastic surgery, and dental.  The cardiology, trauma and general surgery segments are expected to lead the hemostatic agent market during the forecast period. Their leading position can be attributed to factors such as increase in patient population and rise in the number of surgical interventions required in these specialties.

On the basis of size of hospitals, the market is segmented into large hospitals (500 + Beds), medium hospitals (250-499 Beds), small hospitals (Less than 250 Beds). Large hospitals, followed by medium hospitals are anticipated to hold a substantial share in the market. State of the art facilities, well-equipped infrastructure, ability to process high surgery volume, are factors that enable these segments to hold prominent share in the global market.

Hemostatic Agents Market by Region 

The global market has been segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America holds the major share of the global market and is expected to hold its dominant position by the end of the forecast period. Increasing number of surgical procedures, and increase in patient population coupled with the presence of key players and products and a strong focus on research and development activities, are some of the key factors fueling the market growth in the U.S.. Asia Pacific region is expected to witness the highest CAGR during the forecast period. Rising medical tourism and increasing number of surgical procedures, increasing patient population opting for minimally invasive procedures is expected to present a lucrative growth scenario for the hemostatic agents market in this region.

Hemostatic Agents Market Prominent Players 

The prominent players in the global market are Baxter, Ethicon US, LLC, C. R. Bard, Inc., B. Braun Melsungen AG, Pfizer Inc., Z-Medica, LLC, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc. GELITA AG.

Table of Contents

    1. Market Definition
    2. Market Ecosystem
      1.   Market Classification
      2.   Geographic Scope
      3.   Years Considered for the Study
        1. Historical Years – 2016 & 2017
        2. Base Year – 2018
        3. Forecasted Years – 2019 to 2030
    3. Currency Used for the Study
    1. Research Framework
    2. Data Collection Technique
    3. Data Sources
      1.  Secondary Sources
      2.  Primary Sources
    4. Market Estimation Methodology
      1.   Bottoms Up Approach
      2.   Top Down Approach
    5. Data Validation and Triangulation
      1.   Market Forecasting Model
      2.   Limitations/Assumptions of the Study
    1. Overview
    2. Drivers
    3. Barriers/Challenges
    4. Opportunities
    1. Regulatory/Reimbursement Scenario (Key Countries)
    2. Comparative Assement of Key Products
    3. Pricing Analysis by Type
    4. Key Distributors (Snapshot)
  6. Global Market  - Analysis & Forecast, By Product Type
    1. Active
    2. Passive
    3. Combination
  7. Global Market  - Analysis & Forecast, By Specialty
    1. Cardiology
    2.  Cath Lab
    3.  Trauma
    4.  General Surgery
    5.  Obgyn
    6.  Transplant
    7.  Oncology
    8. Neurology
    9. Orthopedic
    10. Plastic Surgery
    11.  Dental
    12.  Others 
  8. Global Market  - Analysis & Forecast, By Size of Hospitals
    1. Large Hospitals (500 + Beds)
    2. Medium Hospitals (250-499 Beds)
    3. Small Hospitals (Less than 250 Beds)
  9. Global Market  - Analysis & Forecast, By Region
    1.  North America Market
      1.   North America Hemostatic Agents Market , By Country
        1. US
        2. Canada
      2. North America Market  Analysis & Forecast, By Product Type
      3. North America Market  Analysis & Forecast, By Specialty
      4. North America Market  Analysis & Forecast, By Size of Hospitals
    2. Europe Market
      1. Europe Hemostatic Agents Market , By Country/Region
        1. Germany
        2. U.K
        3. France
        4. Rest of Europe (ROE)
      2. Europe Market  Analysis & Forecast, By Product Type
      3. Europe Market  Analysis & Forecast, By Specialty
      4. Europe Market  Analysis & Forecast, By Size of Hospitals
    3. Asia Pacific Market
      1. Asia Pacific Hemostatic Agents Market , By Country/Region
        1. China
        2. Japan
        3. India
        4. Rest of Asia Pacific (RoAPAC)
      2. Asia Pacific Market  Analysis & Forecast, By Product Type
      3. Asia Pacific Market  Analysis & Forecast, By Specialty
      4. Asia Pacific Market  Analysis & Forecast, By Size of Hospitals
    4. Rest of the World (ROW) Market
      1. Rest of the World Hemostatic Agents Market , By Country/ Region
        1.  Latin America
        2.  Middle East & Africa
      2. Rest of the World Market  Analysis & Forecast, By Product Type
      3. Rest of the World Market  Analysis & Forecast, By Specialty
      4. Rest of the World Market  Analysis & Forecast, By Size of Hospitals
    1. Market Share Analysis (2018)
    2. Key Strategies Assessment
      1. New Product Launches
      2. Merger & Acquisitions
      3. Agreements, Collaborations, & Partnerships
      4. Expansions
      5. Other Strategies
  11. COMPANY PROFILES (Business Overview, Products/Services Offered, Financial Performance, R&D Intensity, Marketing & Sales Intensity, Recent Developments, Analyst Corner)*
    1. Baxter
    2. Ethicon US, LLC
    3. C. R. Bard, Inc.
    4. B. Braun Melsungen AG
    5. Pfizer Inc.
    6. Z-Medica, LLC
    7. CryoLife, Inc.
    8. Integra LifeSciences
    9. Advanced Medical Solutions Group plc.
    10. GELITA AG.

*Financial details might not be captured in case of privately-held companies or for companies that do not report this information in public domain